Effect of Sevelamer and B. longum on Insulin Sensitivity in Participants With Obesity: A Randomized Clinical Trial
Primary result · Change in M, participants with obesityResult — go to the resultDifference +2.176 mg/kg min CI 0.314–4.038Authors' conclusion
Sevelamer improves insulin sensitivity and LDL-C in participants with obesity.
Study context
- Population
- Lean participants and participants with obesity22 lean, 28 with obesity completed
- Comparison
- Sevelamer or synbiotic vs placebo
- Primary endpoint
- Change in peripheral insulin sensitivity (M) by hyperinsulinemic (60 mU/m² min) euglycemic clamp vs placebo
- Follow-up
- 4 weeks
Methodological detailsdouble-blind, placebo-controlled, three-arm parallel-group
- Double-blind
- Placebo-controlled
- Three-arm parallel-group
Primary result
Change in M, participants with obesity
Difference
+2.176 mg/kg min
CI 0.314–4.038
P = 0.022
As reported in the abstract
Further findings
| Outcome | Difference (mg/dL) (CI) | P value | |
|---|---|---|---|
| LDL-C, participants with obesitySevelamervs Placebo | −29.675 (−53.794 to −5.556) | P = 0.016 | |
| −100−50050Difference, mg/dL (linear scale) |
LDL-C, participants with obesity
- Synbiotic had no effect on lipids in either group
Markers of endotoxemia
- No changes with any intervention
Plasma metabolites
- Sevelamer increased metabolites linked to improved glucose and lipid metabolism: bile acids, amino acids (citrulline, betaine), NAD+ precursors (trigonelline), xenobiotics (genistein, umbelliferone)
Original publication
Effect of Sevelamer and B. longum on Insulin Sensitivity in Participants With Obesity: A Randomized Clinical Trial. Obesity (Silver Spring). Published 15 May 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →